论文部分内容阅读
目的:观察白蛋白结合型紫杉醇治疗晚期恶性肿瘤的有效性和安全性。方法:经病理组织学或细胞学检查确诊的晚期恶性肿瘤患者45例,其中18例接受白蛋白结合型紫杉醇单药化疗,剂量为130 mg·m-2,加入生理盐水100 ml中静脉滴注,第1和8天给药;27例接受白蛋白结合型紫杉醇联合化疗,奈达铂75 mg·m-2加入生理盐水250 ml中静脉滴注,第1或8天给药,每21天为1周期。按照WHO标准评价近期疗效和毒性反应,Karnofsky评分(KPS)变化评价生活质量(QOL)。用药1周期评价毒性,2周期后评价疗效。结果:全组45例患者共完成化疗189个周期,平均4.2周期/例,均可评价近期疗效和安全性。其中获CR1例,PR18例,SD20例,PD6例,即RR为42.2%(19/45),DCR为86.7%(39/45);22例(48.9%)QOL改善,20例(44.4%)QOL稳定,仅3例(6.7%)QOL下降;Ⅲ/Ⅳ级毒性的发生率为26.7%(12/45),多为中性粒细胞减少。结论:白蛋白结合型紫杉醇对晚期恶性肿瘤有较好疗效,可以改善和稳定晚期恶性肿瘤患者的生活质量,治疗耐受性良好,值得临床推广应用和深入观察。
Objective: To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced malignancies. Methods: Forty-five patients with advanced malignant tumors diagnosed by histopathology or cytology were randomly divided into two groups: 18 patients received single-dose chemotherapy with albumin-binding paclitaxel at a dose of 130 mg · m-2, , Administered on days 1 and 8; 27 patients received albumin-bound paclitaxel plus chemotherapy, nedaplatin 75 mg · m-2 added 250 ml normal saline intravenously, administered on the 1st or the eighth day, every 21 days For 1 cycle. Short-term efficacy and toxicity responses were evaluated according to the WHO criteria and changes in Karnofsky score (KPS) were assessed for quality of life (QOL). Toxicity evaluation of 1 cycle, 2 cycles after the evaluation of efficacy. Results: The complete group of 45 patients completed a total of 189 cycles of chemotherapy, an average of 4.2 cycles / case, can evaluate the recent efficacy and safety. Among them, CR1, PR18, SD20, and PD6 were considered as 42.2% (19/45) and 86.7% (39/45) respectively. Twenty-two patients (48.9% QOL was stable, only 3 cases (6.7%) QOL decreased; Ⅲ / Ⅳ grade toxicity was 26.7% (12/45), mostly neutropenia. Conclusions: Albumin-bound paclitaxel has good curative effect on advanced malignant tumors and can improve and stabilize the quality of life of patients with advanced malignancies. The therapy is well tolerated and worthy of clinical application and in-depth observation.